Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -250.61% is 47% above its 5-year average of -475.26%, near the high end of its 5-year range (-1323.61%–72.63%).
54.81% above its 12-month average of -554.62%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1119.48%.
EBITDA MARGIN
-250.61%
EBITDA MARGIN AVG TTM
-554.62%
EBITDA MARGIN AVG 3Y
-702.47%
EBITDA MARGIN AVG 5Y
-475.26%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+54.81%
CURRENT VS 3Y AVG
+64.32%
CURRENT VS 5Y AVG
+47.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AbCellera Biologics Inc.
Market Cap
$4.13B
EBITDA Margin
-250.61%
TTM Avg
-554.62%
3Y Avg
-702.47%
5Y Avg
-475.26%
Market Cap
$4.09B
EBITDA Margin
-1948.43%
TTM Avg
-2807.95%
3Y Avg
-7106.81%
5Y Avg
-6733.51%
Market Cap
$4.37B
EBITDA Margin
-31.52%
TTM Avg
-36.86%
3Y Avg
-49.55%
5Y Avg
-49.55%
Market Cap
$4.39B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$4.42B
EBITDA Margin
23.00%
TTM Avg
14.06%
3Y Avg
2.00%
5Y Avg
2.94%
Market Cap
$4.56B
EBITDA Margin
9.15%
TTM Avg
-7.04%
3Y Avg
-33.99%
5Y Avg
-33.99%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $4.13B | -250.61% | -554.62% | -702.47% | -475.26% |
| LivaNova PLC (LIVN)vs › | $4.15B | 17.39% | 15.89% | 7.31% | 2.27% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.09B | -1948.43% | -2807.95% | -7106.81% | -6733.51% |
| ICU Medical, Inc. (ICUI)vs › | $3.97B | 14.57% | 8.24% | 9.01% | 11.36% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.37B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | -31.52% | -36.86% | -49.55% | -49.55% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | -14.19% | -47.13% | -77.82% | -97.39% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 23.00% | 14.06% | 2.00% | 2.94% |
| BillionToOne, Inc. (BLLN)vs › | $4.56B | 9.15% | -7.04% | -33.99% | -33.99% |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 7.23% | 7.47% | 7.86% | 7.54% |
Gross Margin
61.6%
EBITDA Margin
-250.6%
Operating Margin
-289.0%
Net Margin
-248.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1119.48% |
| 2026-03-31 | -587.66% |
| 2025-12-31 | -46.07% |
| 2025-09-30 | -770.99% |
| 2025-06-30 | -248.92% |
| 2025-03-31 | -1323.61% |
| 2024-12-31 | -1165.45% |
| 2024-09-30 | -850.90% |
| 2024-06-30 | -756.75% |
| 2024-03-31 | -483.50% |
| 2023-12-31 | -620.37% |
| 2023-09-30 | -719.52% |
| 2023-06-30 | -438.87% |
| 2023-03-31 | -473.70% |
| 2022-12-31 | -104.05% |
| 2022-09-30 | 43.86% |
| 2022-06-30 | -5.13% |
| 2022-03-31 | 72.63% |
| 2021-12-31 | 62.02% |
| 2021-09-30 | -433.73% |
| 2021-06-30 | -10.19% |
| 2021-03-31 | 79.92% |
| 2020-12-31 | 78.58% |
| 2020-09-30 | -8.88% |
| 2020-06-30 | 2.01% |
| 2020-03-31 | -31.69% |
| 2019-12-31 | -46.17% |
| 2019-09-30 | -9.43% |
| 2019-06-30 | -12.82% |
| 2019-03-31 | -12.82% |
